Abstract Integrin a3b1 promotes tumor cell adhesion, migration, and invasion on laminin isoforms, and several clinical studies have indicated a correlation between increased tumoral a3b1 integrin expression and tumor progression, metastasis, and poor patient outcomes. However, several other clinical and experimental studies have suggested that a3b1 can possess anti-metastatic activity in certain settings. To help define the range of a3b1 functions in tumor cells in vivo, we used RNAi to silence the a3 integrin subunit in an aggressive, in vivo-passaged subline of PC-3 prostate carcinoma cells. Loss of a3 integrin impaired adhesion and proliferation on the a3b1 integrin ligand, laminin-332 in vitro. Despite these deficits in vitro, the a3-silenced cells were significantly more aggressive in a lung colonization model in vivo, with a substantially increased rate of tumor growth that significantly reduced survival. In contrast, silencing the related a6 integrin subunit delayed metastatic growth in vivo. The increased colonization of a3-silenced tumor cells in vivo was recapitulated in 3D collagen co-cultures with lung fibroblasts or pre-osteoblast-like cells, where a3-silenced cells showed dramatically enhanced growth. The increased response of a3-silenced tumor cells to stromal cells in co-culture could be reproduced by fibroblast conditioned medium, which contains one or more heparin-binding factors that selectively favor the growth of a3-silenced cells. Our new data suggest a scenario in which a3b1 regulates tumor-host interactions within the metastatic tumor microenvironment to limit growth, providing some of the first direct evidence that specific loss of a3 function in tumor cells can have pro-metastatic consequences in vivo.
Introduction
Prostate cancer is the most common cancer in men in the USA, with 241,740 estimated new cases in 2012, and 28,171 estimated deaths [1] . If distant metastasis has occurred, the five year survival rate for prostate cancer drops from near 100 to around 30 %. Prostate cancer progression involves changes both in the extracellular matrix (ECM) underlying prostate epithelial cells and in the cellular receptors for ECM ligands [2] [3] [4] [5] . Laminins, which are major constituents of the basement membrane beneath prostate epithelial cells, are heterotrimers composed of one a, one b, and one c subunit. In prostatic intraepithelial carcinoma in situ (PIN) lesions, the continuous layer of the basement membrane protein, laminin-332 (a3b3c2; LM-332) becomes discontinuous, and in invasive prostate cancer, LM-332 expression is dramatically downregulated or extinguished [6, 7] . The loss of LM-332, which plays a crucial role in the maintenance of stable epithelial morphology, may be one of the key events that enable the dissemination of prostate tumor cells.
In contrast to the expression of LM-332, two major laminin receptors, a3 and a6 integrins, are frequently maintained in prostate carcinoma [8] . Integrins, the major family of receptors for ECM ligands, are heterodimers containing one a and one b subunit. The a3 subunit pairs with the b1 subunit to form a3b1 integrin, which binds strongly to LM-332, and to laminin-511 (a5b1c1; LM-511) [9] . The a6 integrin subunit preferentially pairs with the b4 subunit to form a6b4, a second major receptor for LM-332. In epithelial cells, a6b4 mediates stable anchorage on LM-332 at hemidesmosomes [10] . In contrast, the a3b1 integrin mediates rapid spreading and migration on LM-332 [11] [12] [13] [14] , but may also contribute to the formation or maintenance of stable epithelia [15] [16] [17] [18] .
In the absence of the b4 subunit, a6 integrin pairs with the b1 subunit instead, and a6b1 integrin binds to a wider array of laminin isoforms, including LM-511 [9] . Like LM-332, the b4 integrin subunit is frequently downregulated during prostate cancer progression, as are other constituents of hemidesmosomes, such as collagen VII and BP180 [6, [19] [20] [21] . In addition, TEM4-18 cells, an aggressive PC-3 prostate carcinoma sub-line selected for enhanced transendothelial migration, were found to have undergone an epithelial-to-mesenchymal transition through upregulation of the transcription factor, ZEB1 [22] , which coordinately represses both b4 integrin and LM-332 expression in TEM4-18 cells [23] . Thus, the general view that emerges is that during progression from PIN lesions to invasive prostate cancer, LM-332 and a6b4 integrin are often lost or reduced; however, malignant cells often retain the capacity to interact with LM-332 and other laminin isoforms through the sustained expression of a3b1 or a6b1 integrins.
Sustained expression of a3 and a6 integrin might provide a growth or survival advantage to prostate carcinoma cells by enabling them to bind to LM-511, which, unlike LM-332, is retained in prostate cancer [24] . For example, androgen receptor expression upregulates a6 integrin, which protects laminin-adherent tumor cells from cell death that would otherwise occur upon PI3K inhibition [25] . LM-511 is also abundant in the perineurium of the nerves that innervate the prostate gland, a route of extraprostatic escape for invasive prostate carcinoma cells [5] , in endothelial cell basement membranes [26] , and in bone marrow stroma [27, 28] . Regulated cleavage of the a6 integrin ectodomain, an event that promotes migration and invasion on laminin isoforms [29] , has been implicated in bone colonization and in invasion and degradation of bone matrix by metastatic prostate carcinoma cells [30, 31] . In contrast to its effect on a6 integrin, de novo androgen receptor expression can reduce (although not extinguish) a3 integrin expression [25] , and reduced a3 expression can correlate with a more metastatic phenotype in prostate tumor cells [32] . However, the relationship between a3 expression and prostate cancer progression is complex [8] , and the literature is divided in general on the role of a3b1 integrin in metastasis [33, 34] . Despite the accumulated evidence that laminin-binding integrins regulate prostate cancer progression, a3 and a6 integrin loss-of-function phenotypes for prostate tumor cells have not yet been described for in vivo assays. Therefore, we created prostate tumor cells with stable, profound, RNAi-mediated silencing of the a3 and a6 integrin subunits. Here we report in vitro and in vivo studies with these cells that provide evidence that a3 integrin can act as a negative regulator of prostate cancer metastatic colonization and suggest divergent roles for a3 and a6 integrin in regulating prostate cancer progression.
Materials and methods

Antibodies and extracellular matrix proteins
Anti-integrin monoclonal antibodies (mAbs) were anti-a2, A2-IIE10 [34] ; anti-a3, A3-X8 [35] , and A3-IIF5 [35] ; and anti-a6, GoH3 (GeneTex). Rat tail collagen I and growth factor reduced Matrigel were from BD Biosciences. Human laminin-332 (LM-332) was purified from SCC-25 squamous cell carcinoma-conditioned medium as described [13] .
Cell culture, RNAi, and retroviral transduction GS689.Li prostate carcinoma cells [22] and LNCaP C4-2B cells (MD Anderson Cancer Center Characterized Cell Line Core Facility) were cultured in 1:1 high glucose DMEM: F12 with 10 % fetal bovine serum (FBS; Valley Biomedical, Inc), 2 mM L-glutamine, 100 U/ml penicillin, 100 lg/ml streptomycin, and 0.1 mM non-essential amino acids (all from Invitrogen). MC3T3-E1 preosteoblastic cells (ATCC) were cultured in MEM alpha medium with 10 % fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin, and 100 lg/ml streptomycin. Primary human lung fibroblast MRC-5 cells (ATCC) were cultured in high glucose DMEM with 10 % fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin, and 100 lg/ml streptomycin.
For RNAi, double stranded oligonucleotides encoding short hairpin RNAs (shRNAs) targeting the human a6 and a3 integrin mRNAs were cloned respectively into (i) the original pSIREN RetroQ retroviral vector (BD Biosciences), which contains a puromycin resistance cassette, or (ii) a modified pSIREN vector containing a hygromycin resistance cassette. Two shRNAs targeting different sequences were tested for a3: the a3si targeting sequence is 5 0 -GGATGACTGTGAGCGGATGAA-3 0 , and a3si-2 targeting sequence is 5 0 -TCACTCTGCTGGTGGACTA TA-3 0 . The a6si targeting sequence is 5 0 -GTATGTAA CAGCAACCTTAAA-3 0 . GS689.Li cells were transduced with these constructs, as previously described [13] . We also transduced cells with a pSIREN hygro vector containing scrambled shRNA control sequence (5 0 -GTAGTGAAG GATCGTAGACGG-3 0 ), which was based on the a3si targeting sequence and selected not to target any human mRNA known to be expressed. After selecting stably transduced cells, integrin-silenced populations were sorted using a FACS Diva (Becton-Dickinson). For doubly silenced cells, a3-silenced GS689.Li cells were transduced with the a6si vector and selected. LNCaP C4-2B cells were transduced with a luciferase cDNA cloned into the pQCXIN retroviral expression vector and selected with G418. These luciferase-expressing C4-2B cells were transduced with an a3 integrin cDNA cloned into the pLXIZ retroviral vector or with the empty pLXIZ vector, and then selected with zeocin. All tumor cell lines were maintained as polyclonal populations. Quantification of dilution series of the GS689.Li cell lines showed that they all had a similar bioluminescences of *320 photons/ (s cell). The empty vector control and a3 over-expressing LNCaP C4-2B cells both had a bioluminescence of *50 photons/(s cell).
Cell surface labeling and immunoprecipitation GS689.Li cells were labeled on ice for 1 h with 0.1 mg/ml sulfo-NHS-LC-biotin (Thermo-Fisher Pierce) in HBSM (20 mM HEPES pH 7.2, 150 mM NaCl, 5 mM MgCl 2 ). Cells were then rinsed and lysed in 1 % Triton X-100 detergent (Sigma-Aldrich) in HBSM containing protease inhibitors (2 mM PMSF, 10 lg/ml aprotinin, 5 lg/ml leupeptin and 5 lg/ml E-64; Roche Diagnostics). Specific integrins were immunoprecipitated from clarified lysates, as previously described [13] , and resolved by SDS-PAGE. Proteins were visualized after transfer to nitrocellulose by blotting with IRDye-800-streptavidin (Rockland Immunochemicals, Inc) diluted 1:6,500 in Aquablock (East Coast Biologics) with 0.15 % Tween-20 (Sigma-Aldrich). Membranes were scanned with an Odyssey infrared imaging system (LI-COR Biosciences).
Adhesion assays
Substrates for adhesion assays were 1 lg/ml LM-332, 20 lg/ml collagen I, 100 lg/ml poly-L-lysine (PLL; positive control) or 10 % heat-inactivated (HI) BSA (negative control). After overnight coating, wells were rinsed and blocked with 10 % HI BSA. Cells were harvested and resuspended to final concentration of 2 9 10 5 cells/ml in serum-free medium (SFM) containing 50:50 DMEM:F12, 0.1 mM non-essential amino acids, 25 mM HEPES, 5 mg/ ml BSA, and 2 mM L-glutamine. Then 100 ll of cell suspension was added to each of four substrate-coated wells per condition in a 96-well plate. After 25 min at 37°C, 5 % CO 2 , wells were rinsed three times with warm SFM, with flicking. Positive control PLL wells were gently rinsed once. Cells remaining after rinses were fixed and quantified by staining with crystal violet, as previously described [13] . Adhesion was expressed as fraction of input cells using adhesion in positive control PLL wells to determine total input.
Metastatic colonization assays
All animal procedures were performed according to the University of Iowa Animal Care and Use Committee policies. Using a 27-gauge needle, 1 9 10 6 wild type or integrin-silenced GS689.Li cells were injected into the tail veins of 6-week-old male SCID/NCr (BALB/C) mice (NCIFrederick) in a volume of 200 ll. Bioluminescent imaging (BLI) was performed in an IVIS100 imaging system (Caliper Life Sciences) after intraperitoneal injection of luciferin (100 ll of 15 mg/ml solution per 10 g) as described previously [36] . Whole body tumor growth rates were measured as follows: a rectangular region of interest was placed around the dorsal and ventral images of each mouse, and total photon flux (photons/sec) was quantified using Living Image software v2.50 (Caliper life sciences). The dorsal and ventral values were summed and plotted weekly for each animal. Kaplan-Meier analysis of survival was performed using Prism 4 (GraphPad Software) on the basis that day 0 was the day of tail vein injections and the end-point was the day of euthanasia as determined by [15 % body weight loss, hind limb paralysis or fracture, or by a total photon flux [2 9 10 9 , a value that initial results indicated reliably predicted death within one week in this model.
Cell spreading assay
Wild type and a3-silenced cells were plated in SFM on glass-bottomed 35 mm dishes (MatTek Corp) that had been coated with 2 lg/ml LM-332 and blocked with SFM. After 30 min to allow for cell attachment and spreading, cells were photographed with a 209 C Plan phase objective on a Leica DMIRE2 inverted microscope using a Hamamatsu ORCA-285 CCD camera. Cell areas were measured using ImageJ [37] .
Proliferation assays Wells were coated with 1 lg/ml LM-332, 20 lg/ml collagen I, or left uncoated. A total of 2,500 cells in 200 ll of SFM was plated in 6 wells per cell type per condition in replicate 96 well plates. On subsequent days, replicate plates were developed by discarding 100 ll from each well and adding 100 ll of solution containing SFM supplemented with 2 % FBS and WST-1 reagent (Roche Diagnostics) diluted 1:10.
Plates were incubated for 1 h at 37°C and absorbance at 440 nm was measured using a plate reader.
Matrigel colony formation assay
Wild type and integrin-silenced GS689.Li cells (3,000 cells in 35 ll of PC-3 growth medium) were mixed with 350 ll of growth factor reduced Matrigel and plated in the wells of 24 well plates. After Matrigel polymerized for 20 min at 37°C/5 % CO 2 , each well was overlaid with 500 ll of PC-3 SFM. Plates were incubated for 2-3 weeks before photographing using the inverted microscope system described above.
3D collagen assays
Neutralized rat tail collagen solution was prepared at 0.8 mg/ml in DMEM by adding appropriate amounts of 109 DMEM concentrate and 1 N NaOH. Next, MRC-5 human lung fibroblasts or MC3T3-E1 murine preosteoblast cells were resuspended at 2.86 9 10 4 cells/ml in the collagen solution, and 350 ll of cell suspension was plated per well in 24 well plates (for a final cell number of 10,000 stromal cells per well). After 20 min at 37°C, wells containing stromal cells, suspended in polymerized collagen, were overlaid with 3,000 tumor cells per well in 500 ll of SFM. In some experiments, the number of stromal cells per well was varied as indicated. In some experiments, stromal cells were omitted and replaced with serum-free fibroblast conditioned medium at various dilutions. After 3-4 weeks, tumor cell growth was quantified by adding fresh SFM with 0.15 mg/ml luciferin and imaging the plate using the IVIS100 instrument.
Heparin sepharose chromatography A freshly confluent 150 cm 2 flask of MRC-5 fibroblasts was rinsed with PBS and refed with 20 ml of serum-free DMEM containing 5 mg/ml BSA. After 3 days, conditioned medium was collected, centrifuged at 490g for 5 min to remove cell debris, and passed through a 0.45 lm filter. HEPES buffer pH 7.2 was added to a final concentration of 50 mM and 3 ml of starting material was reserved for analysis. The remaining conditioned medium was loaded in 1 ml increments to a 0.4 ml column of Heparin sepharose 6 fast flow (GE Healthcare) pre-equilibrated with PBS. The flow-through fraction was saved and reloaded. The final flow-through fraction was saved, and the column was rinsed with 1 ml steps of 0.15, 0.25, 0.5, 1, 1.5, and 2 M NaCl in 20 mM HEPES pH 7.2. Next, 50 ll of 20 mg/ml BSA in 20 mM HEPES was added to each fraction and fractions were dialyzed against two changes of PC-3 SFM in Slide-A-Lyzer MINI Dialysis Devices, 3.5 K MWCO (Thermo Fisher Pierce). Samples of each fraction, diluted 1:8 in SFM, were used in 3D collagen growth assays, as described above.
Results
Specific silencing of a3 and a6 integrin in prostate carcinoma cells
To investigate the a3 and a6 integrin loss-of-function phenotypes in a model of prostate cancer metastatic colonization, we used retroviral RNAi constructs to silence a3 or a6, individually or in combination, in GS689.Li cells, an aggressive, in vivo-passaged subline of PC-3 prostate carcinoma cells [22] . After selection, stably transduced, uncloned populations were FACS-sorted to obtain a3-silenced (GS689.Li-a3si), a6-silenced (GS689.Li-a6si), and a3/a6 doubly silenced (GS689.Li-a3/a6si) cells. Cell surface labeling and immunoprecipitation confirmed the loss of a3 integrin specifically in a3-silenced cells (Fig. 1a, lanes 2, 4  vs. 1, 3) , and the loss of a6 integrin specifically in a6-silenced cells (Fig. 1a, lanes 7, 8 vs. 5, 6 ). In GS689.Li cells a6 integrin pairs predominantly with b4 subunit. A small amount of a lower molecular weight species, potentially the a6P cleavage product of the a6 integrin subunit [38] , was also detected (Fig 1a, lanes 5-8) . Flow cytometry confirmed that the a3si cells showed an *93 % reduction in a3 expression; the a6si cells showed a *95 % reduction in a6 integrin expression; and the a3/a6si cells showed a C95 % reduction for both subunits. The expression of another integrin, a2b1, was not dramatically altered in the a3 or a6-silenced cells (Fig. 1a, lanes 9-12) .
We next assessed how loss of a3 or a6 integrin affected cell adhesion to their mutual ligand, LM-332. The a3-silenced cells displayed significantly impaired adhesion on LM-332, while the loss of a6 integrin caused a modest reduction in adhesion that was not statistically significant (Fig. 1b) . Adhesion on LM-332 was nearly abolished in cells silenced for both a3 and a6. In contrast, all four cell types displayed robust adhesion on the a2b1 integrin ligand, collagen I (Fig. 1b) . Collectively, these data established that silencing of a3 integrin led to loss of cell adhesion on LM-332. Integrin a6 may also contribute somewhat to initial adhesion on LM-332, but this contribution is most readily apparent when a3 integrin expression has also been depleted. Divergent roles of a3 and a6 integrin in metastatic colonization of prostate carcinoma cells To determine how a3 and a6 integrin may contribute to metastatic colonization, we inoculated GS689.Li wild type (WT), a3si, a6si, and a3/a6si cells into the tail veins of SCID mice (8 mice/cell type). Luciferase expression, present in the wild type parental cells and each of the derived sublines, enabled us to monitor inoculation success and subsequent colonization using bioluminescence imaging (BLI). Immediately after inoculation, BLI confirmed the presence of tumor cells in the lungs of each mouse (Fig. 2a) , and tumor burden was then monitored by BLI at weekly intervals. After 5 weeks, the apparent tumor burden caused by a3si cells appeared much greater than that caused by wild type cells, but the tumor burden caused a6si cells was significantly less than wild type (Fig. 2a) . Interestingly, growth of the doubly silenced a3/a6si cells was significantly greater than that of the wild type cells, and resembled that of the cells silenced for a3 integrin alone.
BLI quantification over the entire 12 week experiment confirmed that the apparent tumor burden in mice inoculated with a3si or a3/a6si cells became significantly greater than the burden in mice inoculated with wild type cells, beginning on week 4 and continuing for the remainder of the experiment (Fig. 2b) . In contrast, tumor growth by a6si cells was delayed and significantly less than wild type cells on week 5. Thereafter, growth of a6si cells increased, and, although the tumor burden in mice with a6si cells remained consistently lower than in mice with wild type cells, the difference was not statistically significant at most time points. However, Kaplan-Meier analysis revealed that survival to endpoint was significantly longer in mice inoculated with a6si cells than in mice inoculated with wild type cells (Fig. 2c) . In addition, in contrast to the other three cell types, no extra-thoracic colonization was observed for a6si cells (Fig. 2d) , suggesting an impaired ability to disseminate beyond the lungs after tail vein inoculation. In contrast to mice harboring the a6si cells, the survival time of mice inoculated with a3si or a3/a6si cells was significantly less than that of wild type mice (Fig. 2c) . Flow cytometric analysis of cells recovered from several independent tumors confirmed that a3 and a6 silencing was maintained in vivo for the duration of the experiment (greater than or equal to 95 % silencing for each integrin subunit, data not shown). Thus, a3 and a6 appear to have divergent functions in this model of prostate cancer metastatic colonization, with a3 acting as a suppressor and a6 acting as a promoter. In cells doubly silenced for a3 and a6, the a3 loss-of-function phenotype predominates.
a3-Silenced tumor cells display enhanced growth response to stromal cells in 3D co-cultures Because of the dramatic phenotype of a3-silenced GS689.Li cells in vivo, we next focused on gaining insight into the basis of a3 integrin's apparent metastasis suppressing function in these cells. Cell spreading assays on Fig. 1 Specific silencing of a3 and a6 integrin subunits in GS698.Li prostate carcinoma cells. a Parental (WT), a3-silenced (a3si), a6-silenced (a6si), and doubly silenced cells (a3/a6si) were surfacelabeled with biotin and extracted with 1 % Triton X-100. Integrins a3b1, a6b4, or a2b1 were immunoprecipitated (Ip) from normalized lysates, and then analyzed by blotting with IRdye 800-streptavidin. b WT, a3si, a6si, and a3/a6si cells were allowed to adhere to wells coated with laminin-332 (LM-332), collagen I (Col I), or BSA for 20 min in serum-free medium. Non-adherent cells were removed by rinsing, and adherent cells were fixed and quantified by staining with crystal violet. Results are presented as a fraction of total cells input, as measured in poly-L-lysine control wells. Two independent trials that gave similar results were pooled (for total of 8 wells per cell type/ condition) Error bars indicate SEM *Significantly less than WT parental cells, ANOVA with Tukey-Kramer t test (p \ 0.001); **Significantly less than WT (p \ 0.001) and significantly less than a3si (p \ 0.05), ANOVA with Tukey-Kramer t test Clin Exp Metastasis (2013) 30:541-552 545 LM-332 confirmed that the ability of a3si cells to respond to LM-332 was dramatically impaired (Fig. 3) . In proliferation assays, parental and a3si cells displayed similar, modest growth in the absence of serum or exogenous extracellular matrix proteins (Fig. 4a) . Plating the cells on LM-332 strongly promoted the ability of the parental cells to grow in serum-free conditions, and this response was partially impaired in the a3si cells (Fig. 4b) . The a3si cells also showed modestly impaired growth on collagen I (Fig. 4c) . Together with the data in Fig. 1 , these data suggested that a3 integrin's ability to promote LM-332-dependent adhesion, spreading, or proliferation may not control GS689.Li cell colonization in vivo, since, in contrast to their impaired performance in these in vitro assays, a3-silenced cells displayed dramatically enhanced metastatic colonization in vivo.
To further explore the basis of the enhanced colonization of the a3-silenced GS689.Li cells, we next assessed the growth of our GS689.Li cell lines in various 3-dimensional (3D) culture settings. When cultured in 3D Matrigel the a3si cells displayed impaired growth compared to the parental cells, in contrast to our in vivo results ( Supplementary Fig. 1 ). Since 3D Matrigel cultures failed to recapitulate in vivo tumor cell responses, we examined alternative 3D culture systems. Tumor cells embedded in or cultured on 3D collagen I in serum-free medium grew poorly, regardless of a3 integrin expression status (not shown; see also Fig. 5g) . In contrast, when we cultured GS689.Li cells in serum-free media on top of a 3D collagen I matrix in which MRC-5 human lung fibroblasts were embedded, we observed the selective expansion of the a3si cells (Fig. 5 a-c) , similar to our in vivo results. This effect was dose-dependent, as a 3.3-fold increase in the number of fibroblasts in the co-culture nearly doubled the growth of the a3si cells, while having a nominal effect on the growth of the parental tumor cells (Fig. 5d) .
To confirm the specificity of the effects of silencing a3 integrin, we developed a second, stably silenced population using an independent a3 targeting shRNA (GS689.Li-a3si-2 cells). Flow cytometry indicated a3si-2 cells retained *40 % of the parental a3 expression level, as compared to the *7 % expression level retained by a3si cells. However, the a3si-2 cells still outgrew the parental cells in the co-culture assay, albeit to a lesser extent than the original a3si cells (Fig. 5e) . Thus, silencing a3 expression with two independent constructs yielded tumor cells that responded with enhanced growth in our co-culture assay. Further control experiments confirmed that the vector used to silence a3 expression did not by itself alter a3 function in in vitro assays and had minimal impact on the growth of GS689.Li cells in vitro or in vivo (Supplementary Fig. 2 ).
To test how our a3-silenced cells would respond to a second relevant stromal cell type, we replaced the MRC-5 fibroblasts with MC3T3-E1 pre-osteoblast-like cells in our co-culture assay. As shown in Fig. 5f , MC3T3-E1 cells also selectively promoted the growth of the a3si cells. We next examined whether functional blockade of a3 integrin in the parental GS689.Li cells could recapitulate the effects of silencing a3 by RNAi. Antibody blockade of a3 integrin on parental cells significantly promoted their growth compared to untreated controls, to an extent that approached the effect of silencing a3 outright (Fig. 5g) . To explore the role of a3 integrin in a second model of aggressive prostate cancer, we assessed a3 integrin expression in the castrate-resistant LNCaP C4-2B cell line. Flow cytometry revealed that C4-2B cells expressed very little a3 integrin (mean fluorescence intensity of 6.3 compared to 3.2 for negative control IgG). We therefore transduced the C4-2B cells with an a3 integrin expression vector to create C4-2B-a3 cells. Flow cytometry confirmed increased a3 expression in C4-2B-a3 cells (mean fluorescence intensity of 52, a value that corresponds to *60 % of the level of a3 expression in GS689.Li parental cells). In our 3D collagen assay, C4-2B-a3 cells and empty vector control cells both showed enhanced growth in the presence of MRC-5 lung fibroblasts. However, the growth of C4-2B-a3 cells was significantly reduced compared to the control cells (Fig. 5g) . Thus, in this second cell system, a3 integrin also appears to exert a growth inhibitory influence in cocultures with stromal cells. Collectively, these data show that a3 integrin can suppress tumor cell growth in response to stromal cells in a variety of different settings. Stromal cells might promote tumor cell growth via cellcell contact or by secreting one or more soluble factors. To begin to explore the mechanism by which stromal cells promote the growth of a3-silenced prostate cancer cells, we examined tumor cell growth on 3D collagen in the presence of different dilutions of MRC-5 fibroblast conditioned medium. Compared to parental cells, which showed a minimal response, the a3-silenced GS689.Li cells displayed a robust, dose-dependent growth response to MRC-5 conditioned medium (Fig. 6a) . Since many growth promoting soluble factors bind to heparin, we next fractionated MRC-5 conditioned medium on heparin sepharose prior to use in tumor cell growth assays on 3D collagen. Compared to the starting material, the heparin sepharose flow-through fraction showed significantly reduced growth-promoting activity, suggesting that one or more heparin-binding growth factors had been depleted from the conditioned medium by passage over the heparin column (Fig. 6b) . Subsequent salt elution steps revealed that one or more heparin-binding growth factors could be eluted from the column, with the greatest activity in the 1 M NaCl fraction (Fig. 6b) . For all fractions that promoted tumor cell growth, the response of the a3-silenced cells was substantially greater than that of the parental cells.
Discussion
The loss-of-function phenotypes for a3 and a6 integrins in prostate cancer had not previously been described in vivo.
Here we show that profound ([90 %) silencing of a3 and a6 integrin subunits produced divergent phenotypes in a metastatic colonization assay. Apart from bone, lung is one of the next most frequent sites of prostate cancer metastasis, with lung metastases found in up to 50 % of patients who have died with advanced disease [39, 40] . Depletion of a6 integrin delayed progressive lung colonization, reduced extra-thoracic dissemination, and enhanced survival, whereas depletion of a3 integrin enhanced colonization and reduced survival time. Since a3 and a6 integrin could potentially compete for ligand binding, it is conceivable that loss of a3 integrin could enhance ligand occupancy of a6 integrins, thereby enabling pro-metastatic Fig. 5 a3 integrin negatively regulates tumor cell growth in 3D cocultures with stromal cells. a, b WT or a3si GS689.Li cells (3,000 cells per well) were plated on 3D collagen in which 10,000 MRC-5 human lung fibroblasts per well had been embedded. After 17 days, cells were photographed with a 49 objective. c A co-culture experiment was performed as described in a, b, and tumor cell number was quantified using bioluminescence imaging (BLI) after 28 days. *Significantly greater than WT, p \ 0.0001, unpaired t test (n = 5 wells/cell type). d WT or a3si tumor cells (3,000/well) were plated on 3D collagen in which 3,000 or 10,000 MRC-5 human lung fibroblasts per well had been embedded. After 24 days, tumor cell number was quantified by BLI. *Significantly greater than WT, p \ 0.0001, unpaired t test (n = 6 wells/cell type). e A co-culture experiment was performed as described in (a, b), but comparing WT to a3si-2 cells, in which residual cell surface a3 is *40 % of WT a3 expression. After 28 days, tumor cell number was quantified by BLI. *Significantly greater than WT, p \ 0.001, unpaired t test (n = 10 wells/cell type). f A co-culture experiment was performed as in a, b, except that 10,000 MC3T3-E1 pre-osteoblast-like cells per well were embedded in collagen instead of 10,000 MRC-5 fibroblasts. After 18 days, tumor cell number was quantified by BLI. *Significantly greater than WT, p \ 0.0001, unpaired t test (n = 6 wells/cell type). a6 integrin functions. However, increased a6 integrin function alone appears unlikely to account for the enhanced colonization of a3-silenced cells, because cells depleted for both a3 and a6 showed enhanced colonization similar to that of cells depleted for only a3 integrin. Interestingly, genetic ablation of tetraspanin CD151, which associates with both a3 and a6 integrins, suppresses spontaneous metastasis in the TRAMP prostate cancer model [41] . It will be important to determine if CD151 0 s pro-metastatic functions in the TRAMP model are exerted through a3 integrin, a6 integrin, or both. PC3 prostate carcinoma, from which our GS689.Li cells are derived, is an androgen receptor (AR)-negative, PTEN-deficient tumor cell type, and Lamb et al. [25] have shown that re-expressing AR in PC-3 cells confers a6b1 integrin-dependent resistance to cell killing by PI 3-kinase inhibitors. Together with Lamb et al., our new data suggests that promoting a3 integrin suppressor functions or blocking a6 integrin promoter functions might represent important therapeutic directions for AR-defective, PTEN-defective prostate cancer.
Several recent studies from Cress and colleagues [5, 29-31, 42, 43] have implicated a6 integrin in promoting metastatic spread, growth, and invasive behavior of prostate cancer cells, by a mechanism that involves a urokinase plasminogen activator (uPA)-mediated cleavage of the a6 integrin ectodomain. Analysis of clinical specimens in numerous reports has also implicated a6 integrin in prostate cancer progression (reviewed in [2, 3, 5, 44] ). In contrast to a6 integrin, which has been consistently linked to prostate cancer progression, the role of a3 integrin is less clear. In one early study, in vitro selection of PC-3 prostate carcinoma cells for enhanced Matrigel invasion yielded a sub-population with reduced a3 integrin expression [32] . These a3-low expressers were reported to display enhanced colonization in vivo as well [32] . Examination of a3 and a6 integrin expression profiles in clinical prostate cancer samples revealed different classes with different combinations of integrin subunit expression [8] . This study suggested that in higher pathological stages, there may be a selection for a6 integrin expression, and against a class of tumors in which a3 is the only laminin-binding integrin expressed. On the other hand, in early stages of prostate carcinoma invasion, neoplastic cells could potentially use a3b1 integrin to adhere and invade through the remnants of the LM-332-rich basement membrane that was deposited by basal prostate epithelial cells [45] , or for collective migration on LM-511, which is retained in invasive prostate cancer [44] . Conflicting data for a3 integrin have been also been reported in several other types of cancer [33] ; however little loss-of-function data has been available until recently. Mitchell et al. [46] recently showed that silencing a3 integrin in MDA-MB-231 breast carcinoma cells impaired tumor growth after subcutaneous or orthotopic fat pad implantation. In this study, reduced cyclooxygenase-2 (COX-2) expression occurred concurrently with a3 integrin silencing, resulting in reduced production of prostaglandin E2 (PGE2) and reduced PGE2-dependent tumor cell invasion and cross-talk to endothelial cells [46] .
Our study reveals that in contrast to the results from the aforementioned breast carcinoma model, loss of a3 expression can promote a more metastatic phenotype in a prostate carcinoma model. Common to both Mitchell et al. and our study are results that suggest that loss of a3 integrin can dramatically influence tumor-host interactions. While loss of a3 in MDA-MB-231 cells reduced the ability of tumor cells to secrete a factor that promotes endothelial cell migration [46] , in GS689.Li prostate cancer cells, loss of a3 appeared to enhance the ability of the tumor cells to respond to one or more heparin-binding growth factors secreted by stromal cells. One appealing candidate factor is hepatocyte growth factor (HGF), given that its receptor is highly expressed by PC-3 cells and can be transactivated by PC-3 cell adhesion on integrin ligands [47] . However, function blocking anti-HGF antibodies failed to influence growth in our 3D co-culture assay (Varzavand and Stipp, unpublished observation). Studies to identify the factors produced by stromal cells that elicit a3 integrin-dependent tumor cell responses are an important future direction. It will also be important to determine the range of different tumor-host responses that are influenced by tumoral a3 integrin expression. Interestingly, loss of a3 expression in endothelial cells enhances pathological angiogenesis and tumor growth by upregulating endothelial cell responsiveness to vascular endothelial growth factor signaling [48] . In addition, genetic deletion of a3 integrin specifically in keratinocytes impaired the ability of the keratinocytes to respond to stromal TGFb during wound healing [49] . Thus, regulating cell responses to autocrine and juxtracrine signaling appears to be an emerging theme for a3 integrin function. Lastly, our data also raise the possibility that a3b1 integrin promotes tumor growth at primary sites, such as the mammary fat pad in Mitchell et al., but can play an opposite role in later colonization events.
In conclusion, our data reveal that a3 integrin can act as a suppressor of metastatic growth by a mechanism that may involve limiting tumor cell response to stromal-derived growth factors. These new data provide an important counterexample to studies implicating a3 integrin as a promoter of metastasis. Our new system should prove useful for exploring this important, contrasting function of a3 integrin in cancer.
